- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01832519
Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF (MRIinfantCF)
MRI Predictors of Infection, Inflammation, and Structural Lung Damage in CF (Cystic Fibrosis)
Our research is comparing the lungs of babies and young children with CF (cystic fibrosis) to those without CF. We are looking at the blood flow in the lungs to help doctors better understand how CF damages lungs and how to prevent this damage in the future. We will use MRI (Magnetic Resonance Imaging) and special blood tests as ways to understand early changes in the lungs of babies and young children with CF. We will look at the special blood tests to see if they can work as signals for the doctors to better understand when changes are happening in the lungs.
For the babies with CF, we will compare MRI images of the lungs to their CT images (also sometimes called CAT scans or Computerized Tomography). We hope that this study will help us reduce the number of X-rays and CT scans children with CF might get in the future. Because MRI's do not use radiation, this could reduce the amount of radiation exposure that children with CF would get over their lifetime.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Cystic fibrosis (CF) is a well characterized multi-organ disease producing mucus obstruction, chronic lung infection, inflammation, and oxidant stress. These processes result in airway damage, chronic pulmonary symptoms, and ultimately death in young adulthood. These processes are largely silent in the infant and toddler CF population, and ultimately result in lung damage and symptoms of CF. Detection and monitoring of lung disease in infants and toddlers with CF is currently limited, and is a major barrier to advancements in care and research for this population.
This study will be performed in CF and non-CF controls age 6 months - 4.5 years, with repeated measures in CF patients over this window. We intend to examine new techniques to evaluate the lung of CF infants based on magnetic resonance imaging (MRI) that incorporates measurements of lung structure and blood flow. In the CF group, we will augment MRI images with CT images to determine structural relationships between MR and CT (a gold standard to assess lung structure in CF). We will correlate imaging data with core peripheral biomarkers of CF using an unbiased, metabolomic and proteomic-based approach. It is hoped that the results of this study will provide support for the use of MRI to monitor lung structure and blood flow in early CF lung disease, potentially providing a modality to monitor disease status independent of radiation exposure.
We hypothesize that MRI of the lung and pulmonary circulation has the potential to serve as a sensitive and portable tool to monitor early CF lung disease. We will examine three functional aspects of pulmonary blood flow (total and regional pulmonary perfusion, vascular resistance, and aortopulmonary collateral blood flow) compared with structural assessment of the lung by MRI and CT.
This proposal couples advancements in magnetic resonance imaging (MRI) techniques with the emerging technologies of metabolomics and proteomics, linking new MR imaging to candidate and novel pathway analysis. We will use the new technologies (metabolomics and proteomics - performed on peripheral blood samples) to determine if altered signaling pathways detected in the blood are related to changes in the lung. We hypothesize that changes in pulmonary perfusion and/or structure can be correlated with peripheral biomarkers identified by metabolomics and proteomic methodology.
Candidate metabolomic pathways that have been shown to segregate CF from non-CF conditions (including oxidative status, purinergic signaling, and glucose metabolism) will be the focus of initial biomarker analysis, with advanced bioinformatic techniques applied to define novel relationships between the metabolome and imaging. Proteomics will serve a validating function, helping to assign enzyme pathways to metabolomics alterations.
The study design includes 30 CF subjects divided into 2 age groups (6 to 12 month old and 24 to 36 month old) who will receive chest CT and High Resolution CT (HRCT) at baseline and 12 months later. They will be compared to 30 age matched non-CF subjects who will have one visit of MRI with contrast. The non-CF group only includes subjects scheduled for MRI for clinical reasons and will have an additional chest imaging at the end of their scheduled MRI. Both groups will have blood drawn to measure metabolomic and proteomic markers.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion criteria:
CF
- Age at enrollment 6 to 12 months or 24 to 52 months.
- Diagnosed with two CF-causing mutations ('severe' mutations, classes 1, 2, or 3).
Non-CF
- Age at enrollment 6 months to 52 months
- Clinically scheduled for MRI neuroimaging
- Negative history of renal abnormalities
Exclusion criteria:
CF
- Pulmonary exacerbation
- Any known intracardiac defects
- Serum creatinine > 1.5 times the upper limit of normal for age
- Cystatin C > 0.53 (cutoff for normal range)
Non-CF
- Active lung disease as determined by assessment of anesthesiologist
- Any known intracardiac defects
- Results of the most recent serum creatinine within past 12 months above normal range for age
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
CF group
Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
|
Non-CF Control
1 chest MRI with contrast and blood for proteomics and metabolomics
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Pulmonary blood flow
Tijdsspanne: CF: Baseline and 1 year; Control: Baseline
|
Comparison of pulmonary blood flow will be done between MRI pair matched subjects.
|
CF: Baseline and 1 year; Control: Baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
comparison of lung structure by MRI and CT
Tijdsspanne: Baseline and one year
|
On CF cohort, comparison of CT to MRI.
|
Baseline and one year
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: John P Clancy, MD, Cincinnati Childrens Hospital Medical Center
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CIN001InfantMRI
- R457-CR11_01 (Ander subsidie-/financieringsnummer: CF FOUNDATION)
- R01HL116226 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Taaislijmziekte
-
Hospital de Clinicas de Porto AlegreOnbekendTaaislijmziekte | Cystic Fibrosis Longexacerbatie | Cystische fibrose bij kinderen | Cystic Fibrosis Met ExacerbatieBrazilië
-
Boston Children's HospitalVoltooidTaaislijmziekte | Aan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis Met Intestinale ManifestatiesVerenigde Staten
-
Rhode Island HospitalCystic Fibrosis FoundationWervingTaaislijmziekte | Aan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis Met Intestinale ManifestatiesVerenigde Staten
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University... en andere medewerkersActief, niet wervendTaaislijmziekte | Aanhankelijkheid, medicatie | Cystic Fibrosis gastro-intestinale ziekte | Cystische fibrose bij kinderen | Cystic Fibrosis LeverziekteVerenigd Koninkrijk, Ierland
-
University of Colorado, DenverCystic Fibrosis FoundationBeëindigdAan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis Longexacerbatie | Cystische fibrose bij kinderenVerenigde Staten
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActief, niet wervendMyocardinfarct | Hartziekten | Hartfalen | Hartinfarct | Taaislijmziekte | Hartfalen, diastolisch | Hartfalen, systolisch | Linkerventrikeldisfunctie | Aan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis gastro-intestinale ziekte | Cystische fibrose van de alvleesklier | Cystische fibrose, long | Cystic...Denemarken
-
Synspira, Inc.BeëindigdLongziekten | Taaislijmziekte | Longziekte | Antibioticaresistente infectie | Aandoening van de luchtwegen | Cystic Fibrosis Longexacerbatie | Longontsteking | Burkholderia-infecties | Long infectie | Multi-antibioticaresistentie | Longontsteking | Longinfectie Pseudomonaal | Cystic Fibrosis Long | Cystic Fibrosis... en andere voorwaardenVerenigd Koninkrijk
-
University Hospitals Cleveland Medical CenterVoltooidTaaislijmziekte | Hepatische steatose | Aan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis Leverziekte | Pancreas SteatoseVerenigde Staten
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeIngetrokkenAan cystic fibrosis gerelateerde diabetes | Cystic Fibrosis Leverziekte | CF - Cystische fibroseVerenigde Staten
-
University Hospital TuebingenVoltooidGecombineerde droog poeder tobramycine en vernevelde colistine-inhalatie bij CF-patiënten (CotoCFII)Cystic Fibrosis Met Pulmonale Manifestaties